Alkermes, Inc. — Patent Portfolio

Verdict Alkermes, Inc.'s portfolio is relatively strong with a low number of expired patents, but faces a significant cliff in 2030 with 1 drug losing exclusivity, including Aristada, resulting in $500 million in revenue at risk.

Portfolio overview Alkermes, Inc. has a total of 29 drugs in its portfolio, with 71 active US patents and no expired US patents. The average vulnerability score is 44, indicating a moderate level of patent protection. The company has 5 ironclad patents and no vulnerable patents, suggesting a robust patent estate. Notably, Alkermes, Inc. has no biologics in its portfolio.

Cliff calendar Alkermes, Inc. faces a significant cliff in 2030, with 1 drug losing exclusivity, including Aristada. This will result in a loss of exclusivity for this key product.

Most exposed drugs Aristada is the most exposed drug in Alkermes, Inc.'s portfolio, with an earliest active patent expiry date of June 24, 2030, and an average vulnerability score of 44. This drug generates $500 million in annual revenue. With a single patent covering this product, Alkermes, Inc. will face significant competition once the patent expires.

Biologic exclusivity Alkermes, Inc. has no biologics in its portfolio, which means it does not have any biologic exclusivity to consider.

Strategic implications Alkermes, Inc. faces $500 million in revenue at risk over the next 5 years, primarily due to the loss of exclusivity for Aristada in 2030. To mitigate this risk, the company may consider lifecycle management strategies such as subQ switches, label extensions, or combination filings to maintain market share and revenue.